CNTO 328

CNTO 328 (sometimes called Anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse proteins) monoclonal antibody being studied in the treatment of advanced kidney cancer and other types of cancer.[1]

Anti-IL-6 chimeric monoclonal antibody works by inhibiting interleukin-6 (IL-6) to reduce inflammation and tumor growth. It binds to IL-6 preventing IL-6 activating IL-6 receptors.

It has undergone a phase I clinical trial in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.[2]

It gave encouraging results in a small trial for advanced ovarian cancer.[3]

Encouraging results have been reported from a phase II trial for relapsed or refractory multiple myeloma.[4]

Contents

See also

Further reading

References

  1. ^ Zaki et al (2004). CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice.. 111. pp. 592–5. doi:10.1002/ijc.20270. PMID 15239138. 
  2. ^ "A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease". http://clinicaltrials.gov/ct2/show/NCT00412321. 
  3. ^ "CNTO 328 Shows Promise For Ovarian Cancer In Small Clinical Trial, Say U.K. Scientists.". 2009. http://healthinfoispower.wordpress.com/2009/04/07/cnto-328-shows-promise-for-ovarian-cancer-in-small-clinical-trial-say-uk-scientists/. 
  4. ^ "A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM)". 2009. http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33250. 

External links

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".